Allogene Therapeutics
Susan Gaffud is an experienced professional in regulatory affairs and biosample operations, currently serving as a Regulatory Affairs Manager at Allogene Therapeutics since November 2022. Prior roles include Assistant Manager of Regulatory Operations at Allakos Inc. and Senior Regulatory Operations Associate at AbbVie, where Susan managed regulatory submissions and filings. Earlier experience encompasses positions at Genentech and Bloom Energy, focusing on biosample coordination and analytical laboratory techniques. Susan holds a Bachelor of Science degree in Molecular, Cell, and Developmental Biology from the University of California, Santa Cruz, and has participated in various roles ensuring compliance with GLP and cGMP standards.
This person is not in the org chart
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.